Articles

End-to-End Support to Advance Gene Therapies for Rare Retinal Diseases

As a promising therapeutic candidate targeting rare inherited retinal diseases was spun out of an academic medical center, Labcorp served an integral role performing analytical testing of their product and ensure the project followed an expedited timeline.

Filed In

Articles
Ophthalmology
Pharma
Phase IIb
Preclinical & Nonclinical
Rare Disease
Stage (Early, PhI-IIa)
Stage (Late, PhIIb-III)
Therapies - Cell
Therapies - Gene